Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04926233 · ClinicalTrials.gov registry record
Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database Study
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 1,371,146
- Enrollment target
NCT04926233 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 1,371,146 participants.
The verdict
NCT04926233 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 1,371,146 participants
- Enrollment target
Study Summary
The primary objectives of the study are to use US and UK data to describe the characteristics of Chronic Obstructive Pulmonary Disease (COPD) patients according to various demographic, lifestyle, clinical, and medication use.
Interventions
- DRUG Tiotropium bromide + Olodaterol
- DEVICE Sp(t)iolto® Respimat®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,371,146 participants |
| Start Date | 2019-11-15 |
| Est. Completion | 2020-04-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04926233
The ClinicalTrials.gov registry entry for NCT04926233 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,371,146 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tiotropium bromide + Olodaterol is the first listed.
NCT04926233 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04926233 about?
NCT04926233 is a clinical study titled "Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database Study". The primary objectives of the study are to use US and UK data to describe the characteristics of Chronic Obstructive Pulmonary Disease (COPD) patients according to various demographic, lifestyle, clinical, and medication use.
What is the current status of trial NCT04926233?
This trial is currently completed. The enrollment target is 1,371,146 participants. The study started on 2019-11-15. Estimated completion is 2020-04-14.
What interventions are being tested in trial NCT04926233?
The interventions under investigation include: Tiotropium bromide + Olodaterol (DRUG), Sp(t)iolto® Respimat® (DEVICE).
Who is sponsoring clinical trial NCT04926233?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.